Alnylam Pharmaceuticals, Inc.

Hello, and thank you for standing by. My name is Ian, and I will be your conference operator today. At this time, I would like to welcome everyone to the Al Nilem Pharmaceuticals Q1 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. I would now like to turn this call over to the company. Please go ahead.

Good morning. I'm Christina Kinch, Chief Corporate Communications Officer at Alnylam. With me today are Yvonne Greenstreet, Chief Executive Officer, Tolga Tangular, Chief Commercial Officer, Pushko Garg, Chief Research and Development Officer, and Jeff Poulton, Chief Financial Officer. For those of you participating via conference call, the accompanying slides can be accessed by going to the events section of the investors page of our website, investors.elnilam.com slash events. During today's call, as outlined in slide two, Avain will offer introductory remarks and provide some general context. Tolga will provide an update on our global commercial progress. Pushko will review pipeline updates, clinical progress, and upcoming milestones. And Jeff will review our financials and guidance before we open the call to your questions. I'd like to remind you that this call will contain remarks concerning our landowner's future expectations, plans, and prospects, which constitute forward-looking statements for the purposes of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those in our most recent periodic report on file with the SEC. In addition, any forward-looking statements represent our views only as to the date of this reporting and should not be relied upon as representing our views of any subsequent date. who specifically disclaim any obligation to update such statements. With that, I'd like to turn the call over to Yvonne. Yvonne?

Thanks, Christine, and thank you, everyone, for joining the call today. The first quarter of 2026 demonstrated continued strength across the business and represents the type of execution that will drive continued growth at our Nilem. Our leadership in PTR amyloidosis was on display having achieved over $900 million in total net revenues from Vutra and Onpatro combined. We also entered into exciting new collaborations that we expect to drive TTR disease awareness and diagnosis and improve overall care pathways for patients. On the R&D side, we continue to progress our deep pipeline of investigational medicines, including the presentation of impactful data for Vutrisran and Zarbisran, at ACC. We also initiated a phase one trial of ALN2232, which is our first adipose-directed RNAi therapeutic and targets ACVR1C. And on the financial front, the more than $1 billion in combined net product revenues generated in Q1 marks our Nilem's first quarter exceeding the threshold in our history an important milestone. We're also reiterating our four-year financial guidance, reflecting continued confidence in the Ambutra CM launch and the strength of our overall portfolio. Our lineup stands apart in biotech with a differentiated model built on a proven, durable innovation engine and strong commercial execution, positioning us for sustained long-term growth. As the leader in RNAi therapeutics, we've established a modular, reproducible approach to drug development and a product engine that has consistently translated scientific innovation into successful medicines. This high-yielding platform, combined with our outsized historical probability of success relative to the industry, will be key to driving future growth. That capability is reflected in a deep pipeline of more than 25 programs currently in clinical development, with continued expansion into new indications and therapeutic areas, along with evolving platform capabilities. Lastly, today, there are six Arnallem-invented medicines that are collectively generating several billion dollars in annual revenues, reaching hundreds of thousands of patients around the world. My colleagues will outline for you the commercial, R&D, and financial progress we made in the first quarter of 2026. All of this progress builds our momentum towards accelerating innovation and scaling our impact as we look to deliver on our recently announced five-year vision, our Nilem 2030. These ambitions are anchored in three strategic pillars. The first is to establish global leadership in TTR while continuing to build a doable franchise. Our second pillar focuses on growing through sustainable innovation, where we aim to deliver therapies that not only slow the progression of disease, but prevent, halt, or reverse it. And a third pillar is scaling with discipline and agility to enable durable, profitable growth. Taken together, our Nilem 2030 represents our strategy to become the leading science-driven, fully integrated global biopharmaceutical company and to maximize the potential of RNAi therapeutics for patients. With that, let me now turn the call over to Tolga for a review of our first quarter commercial performance. Tolga?